Back tract.

BRAF-mutations occur in roughly 5% of biliary tract cancers. Why care? Because the subset of patients with BRAF V600E-mutated unresectable biliary cancer in the ROAR basket trial (n=43) achieved a promising objective response rate of 47% with combo dabrafenib + trametinib with predictable toxicity. | Subbiah, Lancet Oncol 2020


Popular Posts